

March 22, 2022

VIA EMAIL

OTC Markets Group, Inc.
304 Hudson Street, 3rd Floor
New York, NY 10013

Re: Jun An Kang Group Inc., formerly known as Interact Holdings Group, Inc.,
Adequate Current Information

Ladies and Gentlemen:

This firm has been retained by Jun An Kang Group Inc., formerly known as Interact Holdings Group, Inc., a Florida corporation (the "Issuer"), for the purpose of providing this letter with respect to the information publicly disclosed by the Issuer published through the OTC Disclosure and News Services (the "OTC Disclosure"). We have acted as legal counsel to the Issuer for approximately eight months. OTC Markets Group, Inc. is entitled to rely on this letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144I(2) under the Securities Act of 1933. OTC Markets Group, Inc. shall have full and complete permission and rights to publish this letter through the OTC Disclosure for viewing by the public and regulators.

In connection with this letter, we have reviewed the filings made by the Issuer with OTC Disclosure as listed on Schedule A attached hereto (the "Information") and such other corporate records, certificates of officers, certificates of public officials, and other documents and instruments and such questions of law as we have considered necessary or appropriate to require as a basis for the determination expressed herein.

For purpose of this letter, we have assumed (i) the genuineness of all signatures and the authenticity and completeness of all corporate records, certificate of officers, certificates of public officials, and other documents and instruments submitted to us as originals; (ii) the conformity of authentic originals of all corporate records, certificate of officers, certificates of public officials, and other documents and instruments submitted to us certified, conformed, photostatic or facsimile copies thereof and (iii) the accuracy and adequacy of disclosures made to us by the Issuer, the Issuer's management and the Issuer's board of directors. We have no reason to believe that such records, certificates and other documents are not accurate, authentic or reliable and we make no assurances as to the accuracy and adequacy of such documents.

It is our opinion that the Information (i) constitutes "adequate current public information" concerning the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act and (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Information, on its face, appears to comply in all material aspects of the OTC Pink Basic Disclosure Guidelines.

The financial statements contained in the Information are not audited. We have been advised by management that the financial statements were prepared by Caren Currier, a certified public accountant.

The Issuer's transfer agent is Transfer Online, Inc., ("Transfer Online"), with an address at 512 SE Salmon Street, Portland, OR 97214, (503) 227-2950. Transfer Online is registered with the Securities and Exchange Commission. The Issuer has confirmed to us that a stockholder list provided by Transfer Online was used to confirm the number of issued and outstanding shares of common stock. The report of the transfer agent as of March 16, 2022 states that the Issuer had 749,961,987 shares of common stock issued and outstanding.

One of the attorneys at the firm, a U.S. resident, has (i) met, via Zoom, with Hongbin Xu, the principal executive officer, principal financial accounting officer and sole director of the Issuer, (ii) reviewed the Information, and (iii) discussed and reviewed the Information with Hongbin Xu, through an interpreter John Wu. We have no reason to believe that such sources are not reliable.

Our attorneys working with the Issuer are licensed to practice law in the State of California. Accordingly, the foregoing letter applies only insofar as the existing applicable federal laws and the law of the State of California, including the applicable statutory provisions of the California Corporations Code, all applicable provisions of the California Constitution and reported judicial decisions interpreting those laws. We express no opinion as to the laws of any other jurisdiction.

We are permitted to practice before the Securities and Exchange Commission and have not been prohibited from practice thereunder.


To the best of our knowledge, after inquiry of management and the board of directors of the Issuer, neither the Issuer nor, any 5% holder of the Issuer's common stock, or any member of our firm working with the Issuer, is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

Please be advised of the following:

1. We have not received, nor do we have an agreement to receive in the future, shares of the Issuer's stock, in payment for services.
2. We are not currently, nor in the past five years has this firm been, suspended or barred from practicing in any state or jurisdiction. We are not currently, nor in the past five years, has this firm been charged in a civil or criminal case.
3. The Issuer (or its predecessors) is currently a "shell company", as such term is defined in Rule 405 of the Securities Act of 1933, as amended, and Rule 12b-2 of the Exchange Act.

This letter is limited to the matters set forth herein and no opinion may be inferred or implied beyond the matters expressly contained herein. Except as otherwise set forth herein, this opinion is being provided solely for the purpose of determining whether the Issuer has made adequate current information publicly available within the meaning of the Rule 144(c)(2) under the Securities Act of 1933. This letter is rendered solely to Pink Sheets in connection with the Attorney Letter Agreement between the OTC Markets Group, Inc. and this firm, and may not be relied upon by other persons or for other purpose without our prior written consent. This letter may not be filed with any governmental agency or other persons, without obtaining our prior written approval.

Very truly yours,



Mark E. Crone

SCHEDULE A

- (i) the Issuer's Annual Report for the year ended December 31, 2021 posted on OTC Disclosure on March 3, 2022;
- (ii) the Issuer's Quarterly Report-Amended Quarterly Report for the period ending September 30, 2021 posted on OTC Disclosure on March 1, 2021;
- (iii) the Issuer's Quarterly Report for the period ended September 30, 2021 posted on OTC Disclosure on November 22, 2021;
- (iv) the Issuer's Notification of Late Filing regarding the Quarterly Report for the period ended September 30, 2021 posted on OTC Disclosure on November 16, 2021;
- (v) the Issuer's Annual Report – Amended Annual Report 2020 for the year ended December 31, 2020 posted on OTC Disclosure September 2, 2021;
- (vi) the Issuer's Quarterly Report – Amended 2Q2021 Quarterly for the period ended June 30, 2021 posted on OTC Disclosure September 1, 2021;
- (vii) the Issuer's Quarterly Report – Amended Quarterly Report for the quarter ending at June 30, 2021 posted on OTC Disclosure on August 22, 2021;
- (viii) the Issuer's Quarterly Report – Amended Quarterly Report for the quarter ending at March 31, 2021 posted on OTC Disclosure on August 22, 2021;
- (ix) the Issuer's Annual Report - Amended Annual 12/31/2020 for the year ended December 31, 2020 posted on OTC Disclosure on August 22, 2021;
- (x) the Issuer's Quarterly Report – Amended Quarterly Report for the quarter ending at 9/30/2020 posted on OTC Disclosure on August 22, 2021;
- (xi) the Issuer's Quarterly Report – Amended Quarterly Report for the quarter ending at 6/30/2020 posted on OTC Disclosure on August 22, 2021;
- (xii) the Issuer's Quarterly Report – Amended Quarterly Report for the quarter ending at 3/31/2020 posted on OTC Disclosure on August 22, 2021;
- (xiii) the Issuer's Quarterly Report – Amended Quarterly Report for the quarter ending at 6/30/2021 posted on OTC Disclosure on July 28, 2021;
- (xiv) the Issuer's Annual Report – 12/31/2020 posted on OTC Disclosure on July 22, 2021
- (xv) the Issuer's Supplemental Information – custodian statement posted on OTC Disclosure on July 22, 2021;
- (xvi) the Issuer's Quarterly Report – 6/30/2021 posted on OTC Disclosure on July 22, 2021;
- (xvii) the Issuer's Quarterly Report – 3/31/2021 posted on OTC Disclosure on July 22, 2021;
- (xviii) the Issuer's Quarterly Report – 9/30/2020 posted on OTC Disclosure on July 22, 2021;
- (xix) the Issuer's Quarterly Report – 6/30/2020 posted on OTC Disclosure on July 22, 2021;
- (xx) the Issuer's Quarterly Report – 3/31/2020 posted on OTC Disclosure on July 22, 2021;
- (xxi) the Issuer's financial statements for the year ended December 31, 2021 posted on OTC Disclosure on March 3, 2022;
- (xxii) the Issuer's financial statements for the period ending September 30, 2021 posted on OTC Disclosure on March 1, 2021 and November 22, 2021;
- (xxiii) the Issuer's amended financial statements for the year ended December 31, 2020 posted on OTC Disclosure September 2, 2021, August 22, 2021 and July 22, 2021;

- (xxiv) the Issuer's financial statements for the period ended June 30, 2021 posted on OTC Disclosure September 1, 2021, August 22, 2021, July 28, 2021 and July 22, 2021;
- (xxv) the Issuer's financial statements for the period ending March 31, 2021 posted on OTC Disclosure on August 22, 2021 and July 22, 2021;
- (xxvi) the Issuer's amended financial statements for the period ending September 30, 2020 posted on OTC Disclosure on August 22, 2021 and July 22, 2021;
- (xxvii) the Issuer's amended financial statements for the period ending June 30, 2020 posted on OTC Disclosure on August 22, 2021 and July 22, 2021;
- (xxviii) the Issuer's financial statements for the period ending March 31, 2020 posted on OTC Disclosure on August 22, 2021 and July 22, 2021 and
- (xxix) the Issuer's financial statements for the year ended September 30, 2021 posted on OTC Disclosure on June 22, 2021.